Induction and Scoring of Graft-Versus-Host Disease in a Xenogeneic Murine Model and Quantification of Human T Cells in Mouse Tissues using Digital PCR
May 23rd, 2019
Here, we present a protocol to induce and score disease in a xenogeneic graft-versus-host disease (xenoGVHD) model. xenoGVHD provides an in vivo model to study immunosuppression of human T cells. Additionally, we describe how to detect human T cells in tissues with digital PCR as a tool to quantify immunosuppression.
Overview
This protocol outlines the induction and scoring of xenograft-versus-host disease (xenoGVHD) in a mouse model. It provides a method to study human T cell immunosuppression in vivo, enhancing the relevance of findings to clinical applications.
Key Study Components
Area of Science
- Immunology
- Xenotransplantation
- Translational Medicine
Background
- XenoGVHD serves as a model to study human T cell behavior.
- It allows for the testing of immunosuppressive therapies in a relevant biological context.
- The model improves the translation of research findings to human clinical scenarios.
- Standardized scoring ensures reliable and reproducible results.
Purpose of Study
- To establish a reliable xenoGVHD model for research.
- To quantify human T cell immunosuppression using digital PCR.
- To improve the understanding of human immune responses in a controlled environment.
Methods Used
- Induction of xenoGVHD in NSG mice through irradiation.
- Isolation of human peripheral blood mononuclear cells (PBMCs) for injection.
- Standardization of clinical scoring methods for consistency.
- Use of digital PCR for quantifying human T cells in tissues.
Main Results
- Successful induction of xenoGVHD in the mouse model.
- Reliable scoring methods established for assessing disease severity.
- Quantification of human T cells demonstrated through digital PCR.
- Insights gained into the immunosuppressive effects on human T cells.
Conclusions
- The xenoGVHD model is a valuable tool for studying human immunology.
- Standardized methods enhance the reproducibility of results.
- Findings may inform future clinical applications of immunosuppressive therapies.
Frequently Asked Questions
Executive Industry Relevance
The xenogeneic GVHD murine model enables direct in vivo evaluation of human T cell-targeted immunosuppressive therapies, addressing a critical translational gap in preclinical immunology. Standardized clinical scoring and digital PCR-based quantification of human T cells provide robust, reproducible endpoints for therapeutic efficacy and mechanistic de-risking. This platform supports predictive confidence in early discovery and informs risk-adjusted advancement of immunomodulatory candidates for hematological and inflammatory indications.
Strategic Applications in Biopharma R&D
Early Discovery & Target Validation
- Enables interrogation of human T cell-driven pathology in a controlled in vivo context.
- Supports functional validation of immunosuppressive targets using human cells.
- Facilitates mechanistic de-risking by quantifying human T cell persistence and activity.
- Provides predictive confidence for portfolio triage of immunomodulatory assets.
Screening & Assay Development
- Establishes a validated in vivo system for screening candidate immunosuppressive compounds.
- Standardized clinical scoring ensures reproducibility and comparability across studies.
- Digital PCR readouts enable quantitative assessment of human T cell burden in tissues.
- Supports assay scalability and cross-study platform reuse for compound evaluation.
Translational & Preclinical Research
- Aligns preclinical efficacy endpoints with human disease-relevant immune mechanisms.
- Enables continuity from discovery through preclinical validation of immunotherapies.
- Supports translational biomarker development via quantification of human T cells in vivo.
- Reduces late-stage biological risk by modeling human immune responses directly.
Pipeline & Workflow Integration
This model bridges early discovery, lead identification, and preclinical validation for immunosuppressive therapies targeting human T cells.
- Discovery Biology: Supports hypothesis testing and pathway clarification for human T cell-mediated disease.
- Screening: Provides reproducible, quantitative endpoints for candidate compound evaluation.
- Analytics: Digital PCR enables sensitive, specific measurement of human T cell infiltration in mouse tissues.
- Translational Research: Facilitates alignment of preclinical findings with clinical immune biomarkers.
- Enterprise Reuse: Offers a standardized, reusable platform for diverse immunomodulatory programs.
Operational & Enterprise Impact
- Scientific Value: Increases predictive confidence and reduces mechanistic ambiguity in immunology pipelines.
- Operational Value: Delivers standardized, scalable, and reproducible in vivo workflows.
- Strategic Value: Informs go/no-go decisions and enhances capital efficiency by de-risking early-stage assets.
- Portfolio Impact: Enables risk-adjusted prioritization and advancement of immunomodulatory candidates.
Implementation Considerations
- Requires expertise in xenogeneic mouse models and human immune cell handling.
- Demands access to digital PCR instrumentation and validated human-specific primers.
- Necessitates rigorous cross-team standardization of clinical scoring and blinding procedures.
- Adaptation may be needed for different human cell sources or disease contexts.
- Limitations include model-specific immune interactions and requirement for immunodeficient mice.
Biopharma FAQs
Chapters in this video
0:04
Title
0:40
Non-Obese Diabetic (NOD) Scid Gamma (NSG) Mouse Irradiation and Peripheral Blood Mononuclear Cell (PBMC) Injection
2:22
Retro-Orbital Injection
3:24
Clinical Graft Versus Host Disease (GVHD) Scoring
3:58
Genomic DNA Isolation and Human T Cell Quantification
4:59
Results: Representative GVHD Disease Progression and Digital PCR Human T Cell Detection
5:37
Conclusion
